Cerenome, Inc. CNSY
- Market cap
- $14.3M
- P/E
- 0.0×
Follow CNSY
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 255,000.00 | 41,250.00 | 4,687.50 | 667.50 | 348.75 | 371.25 | 108.75 | 24.25 | 23.25 | 4.00 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 1,012,500.00 | 399,375.00 | 101,250.00 | 9,187.50 | 1,335.00 | 2,032.50 | 810.00 | 180.00 | 66.75 | 57.75 |
High Price
|
|||
| 65 | 37 | 37 | 12 | 12 | 14 | 17 | 20 | 21 | 28 |
Employees
|
|||
| 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 5 | 3 | 3 | 7 | 0 | — | 0 | 5 | 6 | 5 |
Revenue
|
|||
| 41.69% | 5.43% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Gross Margin
|
|||
| (22) | (23) | (9) | (3) | (8) | (13) | (20) | (13) | (13) | (22) |
EBT
|
|||
| (473.50%) | (843.66%) | (297.62%) | (46.91%) | (2,719.80%) | 0.00% | (9,051.34%) | (271.04%) | (222.84%) | (429.43%) |
EBT Margin
|
|||
| (22) | (23) | (13) | (11) | (8) | (13) | (20) | (13) | (13) | (22) |
Net Income
|
|||
| 2 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
Depreciation
|
|||
| 0.27 | 13,445.00 | 5,966.00 | 1,891.35 | 25.68 | 0.00 | 3.20 | 39.12 | 21.93 | 1.68 |
Revenue/Sh
|
|||
| (1.27) | (131,259.60) | (488,886.00) | (46,472.28) | (697.57) | (415.43) | (289.64) | (106.00) | (48.75) | (7.25) |
Earnings/Sh
|
|||
| (1.13) | (90,640.00) | (23,950.00) | (1,596.22) | (714.75) | (318.27) | (185.31) | (102.32) | (39.74) | (6.68) |
Cash Flow/Sh
|
|||
| 0.00 | (6,915.00) | (266.00) | (18.11) | (7.88) | (2.54) | (7.27) | (1.27) | (2.60) | (0.01) |
Capex/Sh
|
|||
| (1.13) | (97,555.00) | (24,216.00) | (1,614.32) | (722.63) | (320.80) | (192.59) | (103.59) | (42.34) | (6.69) |
Free CF/Sh
|
|||
| 0.64 | 65,000.00 | 10,450.00 | 313.51 | 256.86 | 335.48 | 92.07 | (10.73) | (33.69) | 1.28 |
Book Value/Sh
|
|||
| 17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 1,114,110.82 | 4.04 | 0.91 | 0.48 | 1.43 | — | 15.44 | 1.18 | 1.31 | 7.61 |
PS Ratio
|
|||
| 472,173.68 | 0.84 | 0.52 | 2.87 | 2.95 | — | 1.26 | 0.00 | 0.00 | 9.93 |
PB Ratio
|
|||
| 1,114,111.84 | 8.20 | 6.50 | (0.37) | 1.19 | — | (8.71) | 0.27 | 1.28 | 6.10 |
EV/Sales
|
|||
| (266,261.41) | (1.13) | (1.46) | 0.36 | (0.77) | — | 0.34 | (0.10) | (0.66) | (1.49) |
EV/FCF
|
|||
| (20) | (18) | (12) | (6) | (8) | (10) | (13) | (13) | (11) | (21) |
Op' Cash Flow
|
|||
| 0 | (1) | 0 | 0 | 0 | 0 | (1) | 0 | (1) | 0 |
Capex
|
|||
| (19) | (20) | (12) | (6) | (9) | (10) | (13) | (13) | (11) | (21) |
FCF
|
|||
| 6 | (4) | (8) | 5 | 1 | 14 | 10 | (1) | (10) | 3 |
Working Cap'
|
|||
| 18 | 14 | 14 | 12 | 7 | 7 | 5 | 4 | 3 | 1 |
Total Debt
|
|||
| 5 | 3 | 9 | (6) | (1) | (12) | (13) | (5) | 0 | (12) |
Net Debt
|
|||
| 11 | 13 | 5 | 1 | 3 | 11 | 6 | (1) | (9) | 4 |
Sh' Equity
|
|||
| (60.98%) | (80.52%) | (54.39%) | (48.46%) | (46.65%) | (78.62%) | (88.44%) | (75.54%) | (144.03%) | (195.02%) |
ROA
|
|||
| (78.38%) | (78.83%) | (38.77%) | 0.00% | (386.95%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
ROIC
|
|||
| (190.12%) | (222.32%) | (165.94%) | (358.37%) | (393.27%) | (193.25%) | (234.65%) | (522.50%) | 252.07% | 903.94% |
ROE
|
|||
Cerenome, Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CLVSQ Clovis Oncology, Inc. | $14.2M | 0.0× | Compare |
| TPST Tempest Therapeutics, Inc. | $14.4M | 0.0× | Compare |
| RVLP RVL Pharmaceuticals PLC | $14.1M | 0.0× | Compare |
| HIND Vyome Holdings, Inc. | $14.5M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| NRSN NeuroSense Therapeutics Ltd. | $14.0M | 0.0× | Compare |
| DARE Dare Bioscience, Inc. | $14.5M | 0.0× | Compare |
| ADAPY Adaptimmune Therapeutics PLC | $14.6M | 0.0× | Compare |
| TVRD Tvardi Therapeutics, Inc. | $14.7M | 0.0× | Compare |
Cerenome, Inc. (CNSY) key facts
- Cerenome, Inc. (CNSY) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Cerenome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.2 million, down 10.5% from fiscal 2024.
- As of September 25, 2026, CNSY traded at $1.99, a market capitalization of $14.3 million.
- Return on equity was 903.9% and debt-to-equity 0.00.
Cerenome, Inc. (CNSY) Latest News
25 Sep
Cerenome, Inc. announced that CNSide Diagnostics, LLC will host a conference call and webcast on Wednesday, September 30, 2026 at 8:30 a.m. ET to provide a business update on CNSide, the cerebrospinal fluid (CSF) diagnostic platform. The briefing will focus on recent commercial developments, including third‑party billing, market access, expansion of the commercial team, and broadening of the diagnostic testing portfolio. CEO Marc H. Hedrick said the CNSide team has made tremendous progress since its launch earlier in 2026 and plans to outline progress toward 2026 goals and growth initiatives. Dial-in numbers for US/Canada and international participants, as well as a webcast link, will be available, and a replay will be posted after the call. CNSide Diagnostics develops and commercializes CNSide tests to detect CNS metastases; Cerenome links diagnostics with therapeutics and AI in its broader CNS oncology platform, including the REYOBIQ program. Near-term positive developments in reimbursement and market access could influence adoption and investor sentiment, but no major strategic overhaul is indicated.
22 Sep
Cerenome, Inc. announced an in-network provider agreement with Blue Cross Blue Shield of Michigan for the CNSide CSF Tumor Cell Enumeration (TCE) assay, effective September 1, 2026. BCBSM serves about 5 million commercial and Medicare Advantage members. With this deal and prior agreements, CNSide now has contracted reimbursement coverage representing roughly 158 million commercial and Medicare Advantage lives, expanding patient access nationwide. CEO Marc Hedrick called the milestone important for broadening access and strengthening the national reimbursement platform. The CNSide CSF Assay Platform enables rapid diagnosis, monitoring, and treatment guidance for leptomeningeal metastases, with support from 12 peer-reviewed publications and the FORESEE clinical study. Since 2020, more than 11,000 CNSide tests have been performed at over 120 U.S. cancer centers. The test is available exclusively through CNSide Diagnostics, LLC. Broadening contracted payer coverage to about 158 million lives substantially expands access and reimbursement for CNSide, likely driving adoption and revenue growth.
10 Sep
Cerenome, Inc. announces up to $20 million financing facility with royalty-based repayment. Financing strengthens capital position while royalty terms link repayments to future revenues.
20 Aug
Cerenome, Inc. presented progress in therapeutics and diagnostics at the 2026 SNO/ASCO CNS Metastases Conference. Conference presentations signal advancements in core therapeutics and diagnostics operations.
14 Aug
Plus Therapeutics reported second quarter 2026 financial results and business update. Quarterly financial results can moderately affect near-term stock movement and investor views.
13 Aug
Cerenome secured an in-network agreement with Health Care Service Corporation, expanding CNSide contracted coverage to over 150 million covered lives. In-network agreement expands CNSide coverage to over 150 million lives, materially improving market access and revenue potential.
31 Jul
Cerenome launches as an integrated CNS oncology company tied to Plus Therapeutics, Inc. (PSTV). Cerenome launch marks a major strategic move expanding Plus Therapeutics CNS oncology operations.
21 Jul
Plus Therapeutics secured a regional coverage agreement with Medical Mutual for its CNSide cerebrospinal fluid assay in metastatic CNS cancer, expanding reimbursement access for the diagnostic test. Regional coverage agreement improves reimbursement access for CNSide assay and may support modest revenue growth.
16 Jul
Plus Therapeutics partners with Genomic Testing Cooperative to integrate next-generation sequencing into the CNSide CSF assay platform for enhanced central nervous system cancer diagnostics. Partnership strengthens CNSide assay with NGS capabilities, supporting incremental diagnostic and competitive gains without immediate major revenue or regulatory shifts.
14 Jul
Plus Therapeutics highlights NCCN CNS Cancers Guidelines update, reinforcing CNSide® clinical role in leptomeningeal metastases monitoring. NCCN guidelines update supports CNSide® use in metastases monitoring, enhancing product credibility.
25 Jun
Plus Therapeutics secured national coverage agreement with Elevance Health for CNSide cerebrospinal fluid assay in metastatic CNS cancer. National coverage expands reimbursement access for CNSide assay and supports revenue growth for Plus Therapeutics.
4 Jun
Plus Therapeutics, Inc. (PSTV) received CAP accreditation for its CNSide CSF assay platform. CAP accreditation for CNSide platform strengthens operational capabilities in cancer diagnostics.
Plus Therapeutics announced CAP accreditation of its CNSide Diagnostics clinical laboratory. CAP accreditation improves CNSide lab credibility and supports broader diagnostic adoption.
26 May
Plus Therapeutics' CNSide Diagnostic Platform demonstrates substantial healthcare cost reductions for leptomeningeal metastases patients. Positive economic data on CNSide platform supports greater adoption and revenue potential for Plus Therapeutics.
19 May
Plus Therapeutics partners with Ephemeral Technologies to deploy an AI execution platform targeting CNS oncology treatments and operations. AI platform partnership supports product innovation and positioning in CNS oncology without immediate major financial or market shifts.
15 May
Plus Therapeutics reported a Q1 net loss while revenue exceeded analyst estimates. Q1 earnings with revenue beat signal moderate effects on near-term financial outlook and market perception.
Plus Therapeutics reported first quarter 2026 financial results and provided business updates on its REYOBIQ clinical program and CNSide commercial rollout. Standard quarterly results combined with clinical and commercial updates produce moderate short-term market and operational effects.
14 May
Plus Therapeutics (PSTV), a brain cancer treatment stock trading at $6, carries an analyst price target of $38, outshining a 242% biotech meme stock. Analyst target implies over 500% upside from $6 price, poised to drive major investor sentiment and stock performance.
8 May
Plus Therapeutics announced an oral presentation showcasing REYOBIQ™ clinical and translational data, demonstrating favorable safety, improved survival, and emerging immunomodulation effects in patients with leptomeningeal metastases. Favorable REYOBIQ data on safety, survival, and immunomodulation in leptomeningeal metastases could significantly advance clinical prospects and drive positive investor sentiment for PSTV.
7 May
Plus Therapeutics, Inc. (PSTV) receives Medicare enrollment approval for CNSide Diagnostic, a targeted liquid biopsy test for central nervous system cancers, enabling billing and reimbursement from Medicare patients. Medicare approval unlocks reimbursement for CNSide, accelerating commercialization, revenue potential, and adoption in CNS cancer diagnostics for PSTV.
28 Apr
Plus Therapeutics, Inc. (PSTV) secured coverage from Blue Shield of California for its CNSide® Cerebrospinal Fluid Assay, enabling reimbursement for patients with metastatic central nervous system (CNS) cancer. Securing reimbursement coverage from a major insurer like Blue Shield of California significantly enhances market access and revenue potential for Plus Therapeutics' CNSide assay.
23 Apr
Plus Therapeutics initiates manufacturing activities with SpectronRx under a Master Services Agreement to support GMP pivotal trial readiness for REYOBIQ™. Securing GMP manufacturing advances REYOBIQ™ pivotal trials, a major step toward FDA approval and commercialization for PSTV's lead CNS cancer therapy.
21 Apr
Plus Therapeutics, Inc. (PSTV) regained compliance with Nasdaq's minimum bid price requirement, satisfying the $1.00 threshold for 10 consecutive trading days. Regaining Nasdaq compliance averts delisting risk, bolstering stock liquidity, investor sentiment, and market visibility.
15 Apr
Plus Therapeutics, Inc. (PSTV) appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to drive market access and commercial execution. Appointing a specialized VP in Value Strategy & HEOR bolsters commercialization capabilities and market positioning.
9 Apr
Plus Therapeutics, Inc. (PSTV) appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to advance its clinical pipeline. Appointing an experienced Chief Development Officer directly bolsters leadership for clinical pipeline advancement, a critical driver of PSTV's future growth and investor sentiment.
8 Apr
Plus Therapeutics, Inc. (PSTV) received U.S. FDA Orphan Drug Designation for REYOBIQ™ to treat pediatric malignant gliomas, providing incentives like seven years of market exclusivity, tax credits, and protocol assistance. FDA Orphan Drug Designation grants REYOBIQ™ key incentives including market exclusivity and development support, significantly advancing PSTV's pipeline in rare pediatric brain cancer and enhancing investor sentiment.
7 Apr
Plus Therapeutics, Inc. (PSTV) receives AMA PLA code for CNSide® CSF Tumor Cell Enumeration Test, facilitating reimbursement and accelerating U.S. commercial adoption. AMA PLA code enables reimbursement and boosts U.S. commercialization of CNSide test, significantly advancing PSTV's revenue potential and market trajectory.
2 Apr
Plus Therapeutics secures Highmark coverage for CNSide CSF Assay, expanding reimbursement to ~75 million covered lives. Highmark coverage expands reimbursement access to 75 million lives, significantly enhancing revenue potential and market reach for CNSide CSF Assay.
19 Mar
Plus Therapeutics to present new analysis at ISPOR showing CNSide® may reduce leptomeningeal metastases healthcare costs by 40%. Economic data demonstrating 40% cost savings for CNSide® in treating leptomeningeal metastases bolsters commercial viability and investor sentiment.
12 Mar
Plus Therapeutics (PSTV) reported break-even earnings for Q4. Break-even Q4 earnings indicate financial improvement that may positively influence investor sentiment and short-term stock performance.